Literature DB >> 19209889

Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.

Pilho Kim1, Liang Zhang, Ujjini H Manjunatha, Ramandeep Singh, Sejal Patel, Jan Jiricek, Thomas H Keller, Helena I Boshoff, Clifton E Barry, Cynthia S Dowd.   

Abstract

The pan class="Chemical">4-nitroimidazole pan class="Chemical">PA-824 is active against aerobic and anaerobic Mycobacterium tuberculosis (Mtb) while 5-nitroimidazoles like metronidazole are active against only anaerobic Mtb. We have synthesized analogues of both 4- and 5-nitroimidazoles and explored their antitubercular activities. The nitro group is required for both activities in all compounds. The key determinants of aerobic activity in the 4-nitroimidazoles include the bicyclic oxazine, the lipophilic tail, and the 2-position oxygen. For the 5-nitroimidazoles, neither the corresponding bicyclic analogue nor addition of a lipophilic tail conveyed aerobic activity. Incorporation of a 2-position oxygen atom into a rigid 5-nitroimidazooxazine provided the first 5-nitroimidazole with aerobic activity. Across both series, anaerobic and aerobic activities were not correlated and Mtb mutants lacking the deazaflavin-dependent nitroreductase (Ddn) retained anaerobic sensitivity to some compounds. Aerobic activity appears to be correlated with efficiency as a substrate for Ddn, suggesting a means of structure-based optimization of improved nitroimidazoles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19209889      PMCID: PMC2765526          DOI: 10.1021/jm801246z

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  18 in total

Review 1.  Prospects for new antitubercular drugs.

Authors:  Ken Duncan; Clifton E Barry
Journal:  Curr Opin Microbiol       Date:  2004-10       Impact factor: 7.934

2.  Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo[2,1-b]oxazoles.

Authors:  Hirofumi Sasaki; Yoshikazu Haraguchi; Motohiro Itotani; Hideaki Kuroda; Hiroyuki Hashizume; Tatsuo Tomishige; Masanori Kawasaki; Makoto Matsumoto; Makoto Komatsu; Hidetsugu Tsubouchi
Journal:  J Med Chem       Date:  2006-12-28       Impact factor: 7.446

Review 3.  Tuberculosis - metabolism and respiration in the absence of growth.

Authors:  Helena I M Boshoff; Clifton E Barry
Journal:  Nat Rev Microbiol       Date:  2005-01       Impact factor: 60.633

4.  A scalable synthesis of a histamine H3 receptor antagonist.

Authors:  Neelakandha S Mani; Jill A Jablonowski; Todd K Jones
Journal:  J Org Chem       Date:  2004-11-12       Impact factor: 4.354

5.  Potential radiosensitizing agents. Dinitroimidazoles.

Authors:  K C Agrawal; K B Bears; R K Sehgal; J N Brown; P E Rist; W D Rupp
Journal:  J Med Chem       Date:  1979-05       Impact factor: 7.446

6.  Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates.

Authors:  Laura E Via; P Ling Lin; Sonja M Ray; Jose Carrillo; Shannon Sedberry Allen; Seok Yong Eum; Kimberly Taylor; Edwin Klein; Ujjini Manjunatha; Jacqueline Gonzales; Eun Gae Lee; Seung Kyu Park; James A Raleigh; Sang Nae Cho; David N McMurray; JoAnne L Flynn; Clifton E Barry
Journal:  Infect Immun       Date:  2008-03-17       Impact factor: 3.441

7.  A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents.

Authors:  Julian G Hurdle; Robin B Lee; Nageshwar R Budha; Elizabeth I Carson; Jianjun Qi; Michael S Scherman; Sang Hyun Cho; Michael R McNeil; Anne J Lenaerts; Scott G Franzblau; Bernd Meibohm; Richard E Lee
Journal:  J Antimicrob Chemother       Date:  2008-08-07       Impact factor: 5.790

8.  In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis.

Authors:  D R Ashtekar; R Costa-Perira; K Nagrajan; N Vishvanathan; A D Bhatt; W Rittel
Journal:  Antimicrob Agents Chemother       Date:  1993-02       Impact factor: 5.191

9.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.

Authors:  L G Wayne; H A Sramek
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

10.  Oxygen depletion induced dormancy in Mycobacterium smegmatis.

Authors:  T Dick; B H Lee; B Murugasu-Oei
Journal:  FEMS Microbiol Lett       Date:  1998-06-15       Impact factor: 2.742

View more
  24 in total

Review 1.  The chemical biology of new drugs in the development for tuberculosis.

Authors:  Clifton E Barry; John S Blanchard
Journal:  Curr Opin Chem Biol       Date:  2010-05-07       Impact factor: 8.822

2.  Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).

Authors:  Joseph Cherian; Inhee Choi; Amit Nayyar; Ujjini H Manjunatha; Tathagata Mukherjee; Yong Sok Lee; Helena I Boshoff; Ramandeep Singh; Young Hwan Ha; Michael Goodwin; Suresh B Lakshminarayana; Pornwaratt Niyomrattanakit; Jan Jiricek; Sindhu Ravindran; Thomas Dick; Thomas H Keller; Veronique Dartois; Clifton E Barry
Journal:  J Med Chem       Date:  2011-07-26       Impact factor: 7.446

3.  Synthesis and Biological Evaluation of Polar Functionalities Containing Nitrodihydroimidazooxazoles as Anti-TB Agents.

Authors:  Kushalava Reddy Yempalla; Gurunadham Munagala; Samsher Singh; Gurleen Kour; Shweta Sharma; Reena Chib; Sunil Kumar; Priya Wazir; G D Singh; Sushil Raina; Sonali S Bharate; Inshad Ali Khan; Ram A Vishwakarma; Parvinder Pal Singh
Journal:  ACS Med Chem Lett       Date:  2015-09-11       Impact factor: 4.345

4.  Synthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives.

Authors:  Matshawandile Tukulula; Rajni-Kant Sharma; Maïa Meurillon; Aman Mahajan; Krupa Naran; Digby Warner; Jianxing Huang; Belew Mekonnen; Kelly Chibale
Journal:  ACS Med Chem Lett       Date:  2012-11-26       Impact factor: 4.345

5.  Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD+) synthetase inhibitors as potential antitubercular agents.

Authors:  Xu Wang; Yong-Mo Ahn; Adam G Lentscher; Julia S Lister; Robert C Brothers; Malea M Kneen; Barbara Gerratana; Helena I Boshoff; Cynthia S Dowd
Journal:  Bioorg Med Chem Lett       Date:  2017-08-08       Impact factor: 2.823

6.  Nitrotriazole- and imidazole-based amides and sulfonamides as antitubercular agents.

Authors:  Maria V Papadopoulou; William D Bloomer; Howard S Rosenzweig; Alexander Arena; Francisco Arrieta; Joseph C J Rebolledo; Diane K Smith
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

7.  The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824.

Authors:  Soledad Bollo; Luis J Núñez-Vergara; Sunhee Kang; Liang Zhang; Helena I Boshoff; Clifton E Barry; Juan A Squella; Cynthia S Dowd
Journal:  Bioorg Med Chem Lett       Date:  2010-11-25       Impact factor: 2.823

Review 8.  Nitroimidazoles for the treatment of TB: past, present and future.

Authors:  Tathagata Mukherjee; Helena Boshoff
Journal:  Future Med Chem       Date:  2011-09       Impact factor: 3.808

9.  Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.

Authors:  Meera Gurumurthy; Tathagata Mukherjee; Cynthia S Dowd; Ramandeep Singh; Pornwaratt Niyomrattanakit; Jo Ann Tay; Amit Nayyar; Yong Sok Lee; Joseph Cherian; Helena I Boshoff; Thomas Dick; Clifton E Barry; Ujjini H Manjunatha
Journal:  FEBS J       Date:  2011-11-14       Impact factor: 5.542

10.  Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.

Authors:  Pilho Kim; Sunhee Kang; Helena I Boshoff; Jan Jiricek; Margaret Collins; Ramandeep Singh; Ujjini H Manjunatha; Pornwaratt Niyomrattanakit; Liang Zhang; Michael Goodwin; Thomas Dick; Thomas H Keller; Cynthia S Dowd; Clifton E Barry
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.